Company: RGNT
Filing Date: 2025-10-24
Form Type: F-1/A
Source: 0001213900-25-101900
Chunk: 244

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-10-24
Form: F-1/A
Chunk 244
---
 generally will be payable in Israeli currency, which can then be converted into non-Israeli currency
and transferred out of Israel. The usual practice in an action before an Israeli court to recover an amount in a non-Israeli currency
is for the Israeli court to issue a judgment for the equivalent amount in Israeli currency at the rate of exchange in force on the date
of the judgment, but the judgment debtor may make payment in foreign currency. Pending collection, the amount of the judgment of an Israeli
court stated in Israeli currency ordinarily will be linked to the Israeli consumer price index plus interest at the annual statutory
rate set by Israeli regulations prevailing at the time. Judgment creditors must bear the risk of unfavorable exchange rates.

<div align='center'>145

WHERE YOU CAN FIND MORE INFORMATION</div>

We have filed with the SEC
a registration statement on Form F-1 under the Securities Act relating to this offering of our Ordinary Shares. This prospectus
does not contain all of the information contained in the registration statement. The rules and regulations of the SEC allow us to omit
certain information from this prospectus that is included in the registration statement. Statements made in this prospectus concerning
the contents of any contract, agreement or other document are summaries of all material information about the documents summarized, but
are not complete descriptions of all terms of these documents. If we filed any of these documents as an exhibit to the registration statement,
you may read the document itself for a complete description of its terms.

Our SEC filings are available
to the public at the SEC’s website at http://www.sec.gov. Upon completion of this offering, we will be subject to the
information reporting requirements of the Exchange Act that are applicable to foreign private issuers, and under those requirements will
file reports with the SEC. As a foreign private issuer, we will be exempt from the rules under the Exchange Act related to the furnishing
and content of proxy statements, and our officers, directors and principal shareholders will be exempt from the reporting and short-swing
profit recovery provisions contained in Section 16 of the Exchange Act. In addition, we will not be required under the Exchange
Act to file reports and financial statements with the SEC as frequently or as promptly as U.S. companies whose securities are registered
under the Exchange Act.

We maintain a corporate website
at http://www.regentis.co.il/. Information contained on, or that can be accessed through, our website does not constitute a part
of this prospectus.

<div align='center'>